Amgen (AMGN) Given a $220.00 Price Target by Jefferies Financial Group Analysts
Amgen (NASDAQ:AMGN) has been given a $220.00 price target by stock analysts at Jefferies Financial Group in a research report issued to clients and investors on Wednesday. The firm currently has a “buy” rating on the medical research company’s stock. Jefferies Financial Group’s price target points to a potential upside of 8.41% from the company’s previous close.
A number of other research firms have also commented on AMGN. Mizuho set a $200.00 price objective on Amgen and gave the stock a “buy” rating in a research note on Tuesday, May 15th. BidaskClub raised Amgen from a “sell” rating to a “hold” rating in a research note on Friday, May 25th. TheStreet raised Amgen from a “c+” rating to a “b-” rating in a research note on Friday, May 25th. Cann reissued a “buy” rating on shares of Amgen in a research note on Friday, June 8th. Finally, Zacks Investment Research raised Amgen from a “hold” rating to a “buy” rating and set a $207.00 price objective on the stock in a research note on Tuesday, June 26th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $202.76.
Shares of AMGN stock opened at $202.93 on Wednesday. The company has a current ratio of 3.39, a quick ratio of 3.12 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $129.13 billion, a P/E ratio of 14.82, a P/E/G ratio of 1.94 and a beta of 1.39. Amgen has a one year low of $163.31 and a one year high of $203.69.
In other news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction on Monday, July 16th. The stock was sold at an average price of $195.71, for a total transaction of $298,457.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.19% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. HRT Financial LLC increased its holdings in Amgen by 23.0% in the second quarter. HRT Financial LLC now owns 2,507 shares of the medical research company’s stock valued at $462,000 after purchasing an additional 469 shares during the last quarter. LFA Lugano Financial Advisors SA bought a new stake in shares of Amgen in the second quarter worth about $209,000. Mainstay Capital Management LLC ADV bought a new stake in shares of Amgen in the second quarter worth about $111,000. Advisors Asset Management Inc. increased its holdings in shares of Amgen by 1.0% in the second quarter. Advisors Asset Management Inc. now owns 69,408 shares of the medical research company’s stock worth $12,812,000 after acquiring an additional 719 shares in the last quarter. Finally, SRS Capital Advisors Inc. increased its holdings in shares of Amgen by 21.3% in the second quarter. SRS Capital Advisors Inc. now owns 2,391 shares of the medical research company’s stock worth $441,000 after acquiring an additional 420 shares in the last quarter. Institutional investors and hedge funds own 77.20% of the company’s stock.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Further Reading: What is a Tariff?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.